Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism.
Duke Clinical Research Institute, 2400 Pratt St, Room 0311, Terrace Level, Durham, NC 27705, USA. grang001@mc.duke.edu
Christopher B
CB
Granger
Luciana V
LV
Armaganijan
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000453:epidemiology; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*
D000925:Anticoagulants; D002316:Cardiotonic Agents